|
Press Releases |
|
|
|
Thursday, June 16, 2016 |
|
Eisai Launches New Oral Suspension Formulation for Antiepileptic Drug Fycompa (Perampanel) in the United States |
Eisai Co., Ltd. announced today that it has launched Fycompa (perampanel) Oral Suspension, a new formulation of its in-house-discovered antiepileptic drug (AED) Fycompa, in the United States. more info >> |
|
Friday, June 3, 2016 |
|
Eisai Inc. Enters Into Collaboration Agreement to Co-Promote Eisai's Anticancer Agent Lenvima in Combination with Evorolimus as Treatment for Advanced Renal Cell Carcinoma in the United States |
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into an agreement with Novartis Pharmaceuticals Corporation, a U.S. affiliate of Novartis AG, to collaborate on commercial and medical affairs activities for Eisai's in-house developed novel anticancer agent Lenvima and the anticancer agent everolimus in the United States. more info >> |
|
Wednesday, June 1, 2016 |
|
AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Field of Gastrointestinal Disease |
AbbVie GK, Eisai Co., Ltd. and its subsidiary EA Pharma Co., Ltd., announced that EA Pharma and AbbVie will commence the co-promotion of fully human anti-TNF-alpha monoclonal antibody HUMIRA for indications in the field of gastrointestinal disease (ulcerative colitis, Crohn's disease, intestinal Behcet's disease) as of today. more info >> |
|
Wednesday, May 25, 2016 |
|
Eisai to Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) |
Eisai Co., Ltd. announced today that it will launch its in-house-discovered antiepileptic drug (AED) Fycompa Tablets 2 mg and 4 mg (perampanel hydrate) as an adjunctive therapy for partial-onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs in Japan on May 26, 2016. more info >> |
|
Tuesday, May 24, 2016 |
|
Eisai to Present New Research on Oncology Products and Pipeline at 52nd Asco Annual Meeting |
Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and Lenvima will be presented during the 52nd Annual Meeting of the American Society of Clinical Oncology. more info >> |
|
Monday, May 16, 2016 |
|
U.S. FDA Approves Additional Indication for Eisai's Anticancer Agent Lenvima in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma |
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. more info >> |
|
Thursday, April 14, 2016 |
|
Aricept Approved in the Philippines for New Indication as Treatment for Dementia with Lewy Bodies |
Eisai Co., Ltd. announced today that its subsidiary in the Philippines, HI-Eisai Pharmaceutical Inc., has received approval for a new indication for the symptomatic treatment of dementia with Lewy bodies (DLB) for anti-Alzheimer's agent Aricept (donepezil hydrochloride) in the Philippines, and has commenced information provision activities. more info >> |
|
Tuesday, April 5, 2016 |
|
Eisai Receives Positive CHMP Opinion on New Indicator for Anticancer Agent Halaven for Treatment of Advanced Liposarcoma |
Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent Halaven (eribulin mesylate) for treatment of adult patients with unresectable liposarcomas. more info >> |
|
Thursday, March 31, 2016 |
|
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain Emerging Markets to Dr. Reddy's Laboratories |
Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the exclusive worldwide development and marketing rights (excluding Japan and Asia) for its investigational anticancer agent E7777 to Dr. Reddy's Laboratories Ltd. more info >> |
|
Wednesday, March 30, 2016 |
|
Eisai Co., Ltd. and Ajinomoto Co., Inc. Announce Establishment of Gastrointestinal Specialty Pharma EA Pharma Co., Ltd. |
Eisai Co., Ltd. and Ajinomoto Co., Inc. announced today that based on the integration agreement signed and announced on October 15, 2015, the gastrointestinal specialty pharma EA Pharma Co., Ltd. will be established through the splitting off of a portion of Eisai's gastrointestinal disease treatment. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Hong Kong International Licensing Show creates cross industry business opportunities
May 2, 2024 15:00 HKT/SGT
|
|
|
World Blockchain Summit: Pioneering Insights and Strategic Partnerships Ignite in Dubai
May 2, 2024 13:35 HKT/SGT
|
|
|
Future of Video in India Sees Much Optimism for Growth with Technology as the Enabler for the Consumer
May 2, 2024 13:00 HKT/SGT
|
|
|
Rockbird media Presents Retail & E-commerce Summit Asia 2024 - 'Retail Revolution: Setting the Landscape Ablaze' in Manila
May 2, 2024 12:42 HKT/SGT
|
|
|
Rockbird media Presents HR Leaders & HR Tech Strategy Meeting 2024: 'Rehumanizing Work with Emerging Technologies' in Manila
May 2, 2024 12:40 HKT/SGT
|
|
|
Tex Cycle Partners with Evolusi Bersatu to Launch Sabah's First Integrated Scheduled Waste Management Facility
May 2, 2024 12:33 HKT/SGT
|
|
|
The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024
May 2, 2024 12:30 HKT/SGT
|
|
|
2024 CAP Consumer Survey Shows Increase in Piracy on Social Media and Messaging Platforms in Asia Pacific
May 2, 2024 11:51 HKT/SGT
|
|
|
Ordify Employs Blockpass to Open Investment to Everyone
May 2, 2024 10:00 HKT/SGT
|
|
|
JuicyBet Launches Its Innovative GambleFi Platform
May 2, 2024 10:00 HKT/SGT
|
|
|
Q&M Dental Enhances Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore
May 2, 2024 11:00 JST
|
|
|
Loop Industries and Ester Industries Ltd. Announce Joint Venture Agreement to Build an Infinite Loop(TM) Manufacturing Facility in India
May 2, 2024 09:30 HKT/SGT
|
|
|
Paltalk to Host First Quarter 2024 Earnings Results Conference Call on Thursday, May 9, 2024 at 9:00 a.m. ET
May 2, 2024 00:28 HKT/SGT
|
|
|
PodcastOne (Nasdaq: PODC) Acquires Exclusive Sales and Distribution Rights to Dumb Gay Podcast
May 2, 2024 00:19 HKT/SGT
|
|
|
Forian Inc. to Announce First Quarter 2024 Results on May 14, 2024
May 2, 2024 00:09 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|